Seviteronel (VT-464) is primarily investigated for its application in the treatment of advanced prostate cancer, particularly castration-resistant prostate cancer (CRPC). It functions as a selective inhibitor of CYP17 lyase, an enzyme crucial for androgen biosynthesis. By blocking this enzyme, it reduces the production of androgens, which are known to fuel the growth of prostate cancer cells. This mechanism makes it a potential therapeutic option for patients who have developed resistance to traditional androgen deprivation therapies. Clinical trials have explored its efficacy and safety, aiming to provide an alternative or adjunct treatment for improving patient outcomes in this challenging cancer subtype.